Integral Health Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Integral Health Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-145,000	Closed	-$9.93M	–	102
2024 Q2	$9.93M	Buy	145,000 +20,000	+16%	+$1.39M	0.94%	34
2024 Q1	$8.65M	Sell	125,000 -50,000	-29%	-$3.44M	0.8%	50
2023 Q4	$12.5M	Buy	175,000 +42,000	+32%	+$2.42M	1.71%	21
2023 Q3	$6.93M	Sell	133,000 -9,000	-6%	-$524K	0.96%	42
2023 Q2	$8.99M	Buy	+142,000	New	+$8.85M	1.11%	37
2022 Q3	–	Sell	-78,277	Closed	-$4.47M	–	81
2022 Q2	$4.47M	Buy	78,277 +38,277	+96%	+$2.17M	0.92%	37
2022 Q1	$2.45M	Buy	+40,000	New	+$2.08M	0.64%	53
2021 Q1	–	Sell	-30,000	Closed	-$954K	–	86
2020 Q4	$954K	Sell	30,000 -70,000	-70%	-$1.84M	0.28%	57
2020 Q3	$2.57M	Buy	+100,000	New	+$2.28M	0.78%	47

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Integral Health Asset Management's ITCI Position: Q3 2024 in Review

Integral Health Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 145,000 shares — an estimated $9.93M sold.

Integral Health Asset Management first reported a position in ITCI in Q3 2020 and held it in 9 quarters. The position peaked at $12.5M in Q4 2023. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

Integral Health Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
Integral Health Asset Management sold 145,000 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $9.93M.
Integral Health Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 9 quarters.
Integral Health Asset Management's Intra-Cellular Therapies Inc. position peaked at $12.5M in Q4 2023.
355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Integral Health Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.